Avio Smart Market Stack Limited has significantly expanded its strategic partnership with Huwel Lifesciences, moving beyond their initial tuberculosis diagnostics focus to launch a comprehensive range of patented molecular diagnostic products across multiple healthcare segments in India. The expanded collaboration, announced through a regulatory filing under SEBI Regulation 30, builds upon their existing shareholders' agreement and positions both companies to address India's broader infectious disease diagnostics market.

Expanded Product Portfolio and Technology Platform

The enhanced partnership encompasses a diverse range of molecular diagnostic solutions developed by Huwel Lifesciences. The company has established itself as a fully indigenous diagnostics innovator with comprehensive in-house capabilities spanning research, assay development, and manufacturing within its own facilities.

Huwel's diagnostic solutions are designed to operate on open RT-PCR systems, enabling utilization of the extensive RT-PCR laboratory infrastructure deployed across India during the COVID-19 pandemic. This approach facilitates scalable testing without requiring significant new infrastructure investments.

Market Opportunity and Scale

The expanded collaboration targets India's substantial infectious disease diagnostics market, which represents one of the largest globally. The market scope extends well beyond the initial tuberculosis focus:

National health programs and institutional healthcare networks conduct tens of millions of diagnostic tests annually across these disease segments, creating substantial commercial opportunities for indigenous diagnostic solutions.

Technology Validation and Cost Advantages

Huwel's tuberculosis diagnostic platform has received comprehensive validation through a Health Technology Assessment conducted by the Department of Health Research under the Ministry of Health & Family Welfare. The assessment demonstrates significant cost advantages:

The platform's compatibility with existing RT-PCR infrastructure positions it for rapid deployment across government health programs, hospital networks, diagnostic laboratories, and private healthcare providers.

Strategic Partnership Structure

Under the collaboration framework, Avio Smart Market Stack Limited holds a minority stake in Huwel Lifesciences and maintains contractual entitlement to receive a defined share of net project revenues generated from orders secured through its institutional engagement efforts. ASMS will leverage its institutional relationships, digital infrastructure capabilities, and experience in executing large-scale programs to support go-to-market strategy and commercialization.

Management Outlook

Commenting on the expanded collaboration, Mr. Vidhyasagar Reddy, Managing Director of Avio Smart Market Stack Limited, stated: "India has a significant opportunity to strengthen its public health infrastructure through indigenous diagnostic innovation. Our collaboration with Huwel Lifesciences brings together advanced molecular diagnostic technologies and our institutional market access capabilities. By leveraging the extensive RT-PCR infrastructure established across the country during the pandemic, we aim to accelerate the availability of rapid, accurate, and affordable diagnostics for diseases such as tuberculosis, HIV, hepatitis, and other infectious conditions."

The partnership aligns with ASMS's broader strategic expansion into the high-growth health-tech sector while supporting the Government of India's "Make in India" initiative through indigenous diagnostic innovation. Over the coming years, both companies expect to introduce multiple diagnostic product lines across different disease segments, expanding healthcare access across India's institutional and private healthcare networks.

Bartronics India , now known as Avio Smart Market Stack Limited, announced significant investment decisions following its Board meeting on February 27, 2026. The company has approved revised investment terms with Huwel Lifesciences Private Limited, marking a strategic expansion into the lifesciences sector through both equity participation and revenue-sharing arrangements.

Investment Structure and Terms

The Board approved a comprehensive investment package worth ₹15,00,00,000 (₹15 crore) to be deployed in a structured manner. The investment will be executed through two equal tranches, providing operational flexibility and risk management.

Strategic Business Collaboration

Beyond the equity investment, the agreement establishes a strategic business collaboration framework between the parties. This collaboration focuses on joint identification, development, and execution of projects in the lifesciences sector.

Under the collaboration terms, Avio Smart Market Stack Limited will be entitled to 40% of the Net Project Revenue derived from projects facilitated or supported by the company or its affiliates. This revenue-sharing arrangement provides the company with ongoing income potential from successful project implementations, creating a sustainable business model beyond the initial equity investment.

Governance and Documentation

The Board has approved the execution of a Share Subscription cum Shareholders' Agreement (SSSHA) with Huwel Lifesciences Private Limited and its promoters. This comprehensive agreement will establish detailed terms and conditions governing the investment and define the inter se rights and obligations of all parties involved.

Regulatory Compliance and Timeline

The investment decision follows the company's earlier intimation dated September 23, 2025, and received consent from the Audit Committee prior to Board approval. The transaction does not constitute a related party transaction, as confirmed in the regulatory disclosures.

The Board meeting commenced at 2:30 PM and concluded at 3:15 PM on February 27, 2026. All decisions were made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full regulatory compliance and transparency for stakeholders.